98 related articles for article (PubMed ID: 20127663)
1. The tocotrienol-rich fraction from rice bran enhances cisplatin-induced cytotoxicity in human mesothelioma H28 cells.
Nakashima K; Virgona N; Miyazawa M; Watanabe T; Yano T
Phytother Res; 2010 Sep; 24(9):1317-21. PubMed ID: 20127663
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms mediating the synergistic anticancer effects of combined γ-tocotrienol and sesamin treatment.
Akl MR; Ayoub NM; Sylvester PW
Planta Med; 2012 Nov; 78(16):1731-9. PubMed ID: 22987298
[TBL] [Abstract][Full Text] [Related]
4. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y
J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells.
Tuerdi G; Ichinomiya S; Sato H; Siddig S; Suwa E; Iwata H; Yano T; Ueno K
Cancer Lett; 2013 Oct; 339(1):116-27. PubMed ID: 23879968
[TBL] [Abstract][Full Text] [Related]
6. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells.
Kashiwagi K; Virgona N; Harada K; Kido W; Yano Y; Ando A; Hagiwara K; Yano T
Life Sci; 2009 May; 84(19-20):650-6. PubMed ID: 19232361
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
[TBL] [Abstract][Full Text] [Related]
8. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.
Samant GV; Sylvester PW
Cell Prolif; 2006 Dec; 39(6):563-74. PubMed ID: 17109639
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anticancer effects of combined γ-tocotrienol and oridonin treatment is associated with the induction of autophagy.
Tiwari RV; Parajuli P; Sylvester PW
Mol Cell Biochem; 2015 Oct; 408(1-2):123-37. PubMed ID: 26112904
[TBL] [Abstract][Full Text] [Related]
10. Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity.
Shah SJ; Sylvester PW
Exp Biol Med (Maywood); 2005 Apr; 230(4):235-41. PubMed ID: 15792944
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
McDonald GT; Sullivan R; Paré GC; Graham CH
Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis.
Parajuli P; Tiwari RV; Sylvester PW
Biol Pharm Bull; 2015; 38(9):1352-60. PubMed ID: 26328490
[TBL] [Abstract][Full Text] [Related]
13. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
[TBL] [Abstract][Full Text] [Related]
14. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
[TBL] [Abstract][Full Text] [Related]
15. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
Mitsuuchi Y; Johnson SW; Selvakumaran M; Williams SJ; Hamilton TC; Testa JR
Cancer Res; 2000 Oct; 60(19):5390-4. PubMed ID: 11034077
[TBL] [Abstract][Full Text] [Related]
16. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
17. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Hartmann W; Küchler J; Koch A; Friedrichs N; Waha A; Endl E; Czerwitzki J; Metzger D; Steiner S; Wurst P; Leuschner I; von Schweinitz D; Buettner R; Pietsch T
Clin Cancer Res; 2009 Jul; 15(14):4538-45. PubMed ID: 19584164
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
19. Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy.
Sylvester PW; Ayoub NM
Anticancer Agents Med Chem; 2013 Sep; 13(7):1039-47. PubMed ID: 23272909
[TBL] [Abstract][Full Text] [Related]
20. Synergistic increase in efficacy of a combination of 2-deoxy-D-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis.
Jalota A; Kumar M; Das BC; Yadav AK; Chosdol K; Sinha S
Tumour Biol; 2016 Sep; 37(9):12347-12358. PubMed ID: 27306214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
